Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Ewing's sarcoma and related subtypes of primitive neuroectodermal tumours share a recurrent and specific t(11;22) (q24;q12) chromosome translocation, the breakpoints of which have recently been cloned. Phylogenetically conserved restriction fragments in the vicinity of EWSR1 and EWSR2, the genomic regions where the breakpoints of chromosome 22 and chromosome 11 are, respectively, have allowed identification of transcribed sequences from these regions and has indicated that a hybrid transcript might be generated by the translocation. Here we use these fragments to screen human complementary DNA libraries to show that the translocation alters the open reading frame of an expressed gene on chromosome 22 gene by substituting a sequence encoding a putative RNA-binding domain for that of the DNA-binding domain of the human homologue of murine Fli-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ewing’s sarcoma, a common pediatric cancer, is invariably associated with ETS gene translocations (182) that result in a fusion oncogene consisting of the 5′ end of EWS and the 3′ end of FLI1, or less frequently ERG, ETV1, ETV4, or FEV (Figure 1a) (183, 184).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [183]
Citations
Cites
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
Transcriptional Regulation in Mammalian Cells by Sequence-Specific DNA Binding Proteins
Mitchell, P. J., & Tjian, R. (1989) · Science · doi:10.1126/science.2667136 · Cited by 3,114
RNA recognition: towards identifying determinants of specificity
Kenan, D. J., Query, C. C., & Keene, J. D. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90088-d · Cited by 730
RNA-binding proteins as developmental regulators.
Bandziulis, R. J., Swanson, M. S., & Dreyfuss, G. (1989) · Genes & Development · doi:10.1101/gad.3.4.431 · Cited by 644
Turc-Carel, C., Aurias, A., Mugneret, F., Lizard, S., Sidaner, I., Volk, C., Thiery, J. P., Olschwang, S., Philip, I., Berger, M. P., et al. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90285-3 · Cited by 466
Self-citationBen-David, Y., Giddens, E. B., Letwin, K., & Bernstein, A. (1991) · Genes & Development · doi:10.1101/gad.5.6.908 · Cited by 403
Chromosome Translocation in Peripheral Neuroepithelioma
Whang-Peng, J., Triche, T. J., Knutsen, T., Miser, J., Douglass, E. C., & Israel, M. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198408303110907 · Cited by 399
Chromosomal Translocations in Ewing's Sarcoma
(1983) · New England Journal of Medicine · doi:10.1056/nejm198308253090817 · Cited by 330
Corden, J. L. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90236-5 · Cited by 327
Turc-Carel, C., Philip, I., Berger, M.-P., Philip, T., & Lenoir, G. M. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90002-5 · Cited by 291
Research works printed but not linked: 8
- Aurias, A., Rimbaut, C., Buffe, C., Dubousset, J. & Mazabraud, A. N. Engl. J. Med. 309, 496–497 (1983).
- Turc-Carel, C., Philip, I., Berge, R. M. P., Philip, T. & Lenoir, G. M. N. Engl. J. Med. 309, 497–498 (1983).
- De Chadarevian, J. P., Vekemans, M. & Seemayer, T. A. N. Engl. J. Med. 311, 1702–1703 (1984).
- Cavazzana, A. O. et al. Adv. Neuroblastoma Res. 2, 463–473 (1988).
- Zucman, J. et al. Genes Chrom. Cancer (in the press).
- Douglass, E. C., Valentine, M., Green, A. A., Hayes, F. A. & Thompson, E. I. J. natn. Cancer Inst. 77, 1211–1213 (1986).
- Watson, D. K., Ascione, R. & Papas, T. S. Crit. Rev. Oncogenesis 1, 409–436 (1990).
- Rouleau, G. A. et al. Am. J. hum. Genet. 46, 323–328 (1990).
Cited by
Items 801–900 of 1,002
The Novel Epithelial-Specific Ets Transcription Factor Gene ESX Maps to Human Chromosome 1q32.1
Oettgen, P., Carter, K. C., Augustus, M., Barcinski, M. A., Boltax, J., KUNSCH, C. A., & Libermann, T. A. (1997) · Genomics · doi:10.1006/geno.1997.4974 · Cited by 34
Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells
Caropreso, V., Darvishi, E., Turbyville, T. J., Ratnayake, R., Grohar, P. J., McMahon, J. B., & Woldemichael, G. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.701375 · Cited by 32
“Reciprocal chromosomal translocations, t(11; 22) (q24;q12), that result in the fusion of the transactivational domain of EWS and the DNA binding domain of FLI1, an ETS transcription factor, generating the chimeric EWS-FLI1 fusion transcript underlie an overwhelming majority of cases of Ewing sarcoma (1).”
BackgroundPrimitive Neuroectodermal Tumor of the Stomach
Soulard, R., Claude, V., Camparo, P., Dufau, J.-P., Saint-Blancard, P., & Gros, P. (2005) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2005-129-107-pntots · Cited by 32
EWS/FLI1 suppresses retinoblastoma protein function and senescence in Ewing's sarcoma cells
Hu, H., Zielinska‐Kwiatkowska, A., Munro, K., Wilcox, J. J., Wu, D. Y., Yang, L., & Chansky, H. A. (2008) · Journal of Orthopaedic Research® · doi:10.1002/jor.20597 · Cited by 33
“Keywords: Ewing’s sarcoma; EWS/FLI1; retinoblastoma; senescence; cyclin D1 In over 85% of Ewing’s Family Tumors (EFTs), a specific t(11;22) chromosomal translocation results in a chimeric oncogenic product fusing the N-terminal domain of the RNA-binding protein EWS with the C-terminal DNAbinding domain of the ETS fami…”
BackgroundInfluentialFamilial risk for histology-specific bone cancers: An updated study in Sweden
Ji, J., & Hemminki, K. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.11.043 · Cited by 35
Variant EWS-WT1 Chimeric Product in the Desmoplastic Small Round Cell Tumor
Chan, A. S. W., MacNeill, S., Thorner, P. S., Squire, J. A., & Zieleńska, M. (1999) · Pediatric and Developmental Pathology · doi:10.1007/s100249900108 · Cited by 32
“Tumor tissue was also screened for the presence of fusion transcripts characteristic of other pediatric tumors, including EWS/FLI1 of Ewing sarcoma and pPNET [16], and PAX3/FHKR and PAX7/FHKR of alveolar rhabdomyosarcoma (RMS-A) [14,15].”
BackgroundEpigenetic plasticity, selection, and tumorigenesis
Flavahan, W. A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20191215 · Cited by 32
Targeting metastasis in paediatric bone sarcomas
Bull, E. C., Singh, A., Harden, A. M., Soanes, K., Habash, H., Toracchio, L., Carrabotta, M., Schreck, C., Shah, K. M., Riestra, P. V., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02365-z · Cited by 42
“In Ewing sarcoma, FET :: ETS gene fusions, most commonly EWSR1 :: FLI1 [25], are generated either by balanced chromosomal translocations or loop like rear-rangements [26] termed chromoplexy [27].”
Oncogenic fusion proteins adopt the insulin-like growth factor signaling pathway
Werner, H., Meisel-Sharon, S., & Bruchim, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0807-z · Cited by 31
Pioneer factors in development and cancer
Sunkel, B. D., & Stanton, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103132 · Cited by 33
Targeted siRNA nanocarrier: a platform technology for cancer treatment
Bäumer, N., Tiemann, J., Scheller, A., Meyer, T., Wittmann, L., Suburu, M. E. G., Greune, L., Peipp, M., Kellmann, N., Gumnior, A., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02241-w · Cited by 31
“The key genetic event in Ewing sarcoma is a chromosomal translocation t(11;22) that results in the formation of the fusion protein EWS-FLI1 which acts as driver of tumour growth [14].”
BackgroundThe Molecular Biology of Soft Tissue Sarcomas: Current Knowledge and Future Perspectives
Vibert, J., & Watson, S. (2022) · Cancers · doi:10.3390/cancers14102548 · Cited by 36
“The paradigm of this model of oncogenesis is Ewing sarcoma [6]: this tumor which develops from bone but also soft tissues in young adults and adolescents is characterized by a translocation between chromosomes 11 and 22, giving rise to a fusion gene EWS-FLI1, leading to a chimeric transcription factor with oncogenic p…”
BackgroundMooney, B., Negri, G. L., Shyp, T., Delaidelli, A., Zhang, H., Miko, S. E. S., Weiner, A. K., Radaoui, A. B., Shraim, R., Lizardo, M. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2187 · Cited by 33
Grünewald, T. G. P., Willier, S. M., Janik, D., Unland, R., Reiß, C., da Costa, O. P., Buch, T., Dirksen, U., Richter, G. H. S., Neff, F., et al. (2013) · Biology of the Cell · doi:10.1111/boc.201300041 · Cited by 31
“…expression of chimeric Ewing sarcoma breakpoint region 1/E-twenty-six (EWS/ETS) fusion proteins derived from chromosomal translocations with Ewing sarcoma breakpoint region 1/friend leukaemia virus integration 1 (EWS/FLI1) being the predominant mutation (85% of cases) (Delattre et al., 1992, 1994).”
BackgroundCollini, P., Mezzelani, A., Modena, P., Dagrada, G. P., Tamborini, E., Luksch, R., Gronchi, A., Navarria, P., Sozzi, G., & Pilotti, S. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200308000-00016 · Cited by 31
Wojtalla, A., Salm, F., Christiansen, D. G., Cremona, T. P., Ćwiek, P., Shalaby, T., Groß, N., Grotzer, M. A., & Arcaro, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047109 · Cited by 35
“Common intracellular signaling pathways and chromosomal deletions including 1p36 and 11q loss have been previously identified in different embryonal tumors, including medulloblastoma and neuroblastoma [1–10].”
BackgroundHigh-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility
Pattenden, S. G., Simon, J. M., Wali, A., Jayakody, C. N., Troutman, J. A., McFadden, A. W., Wooten, J., Wood, C. C., Frye, S. V., Janzen, W. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521827113 · Cited by 35
“…of Ewing sarcomas, highly malignant pediatric bone and soft tissue tumors, harbor a chromosomal translocation that joins the amino-terminal domain of EWSR1 with the DNA binding domain of the ETS transcription factor family member FLI1 to generate the chimeric transcription factor EWSR1-FLI1 (15).”
BackgroundThe histogenesis of Ewing Sarcoma
Tu, J., Huo, Z., Gingold, J. A., Zhao, R., Shen, J., & Lee, D. (2017) · Cancer Reports and Reviews · doi:10.15761/crr.1000111 · Cited by 32
“Around 85% of Ewing sarcoma harbors a t(11:22)(q24:q12) translocation resulting in the fusion of the N-terminal portion of the EWS gene with the C-terminal portion of the FLI1 gene, one of five ETS family genes [3].”
BackgroundWan, Z., Huang, Z., & Chen, L.-B. (2017) · Sao Paulo Medical Journal · doi:10.1590/1516-3180.2017.0236230917 · Cited by 31
“It has been reported that the t(11;22) (q24;q12) translocation is found in 85% of cases of Ewing’s sarcoma.”
BackgroundMitra, P., Eckenrode, J. M., Mandal, A., Jha, A. K., Salem, S. M., Leggas, M. L., & Rohr, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01107 · Cited by 31
Miele, E., Vito, R. D., Ciolfi, A., Pedace, L., Russo, I., Pasquale, M. D. D., Giannatale, A. D., Crocoli, A., Angelis, B. D., Tartaglia, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051818 · Cited by 32
“EWSR1–FLI1 or EWSR1–ERG are the most common translocations in ES and are observed in ~85%–90% and 5%–10% of all cases, respectively [3,4].”
BackgroundOberlin, O., Bayle, C., Hartmann, O., Terrier-Lacombe, M.-J., & Lemerle, J. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950240602 · Cited by 31
Pineau, P., Marchio, A., Terris, B., Mattéi, M., Tu, Z., Tiollais, P., & Dejean, A. (1996) · Journal of Virology · doi:10.1128/jvi.70.10.7280-7284.1996 · Cited by 31
“Four HBV-mediated chromosomal translocations, t(17;18), t(5;9), t(X;17), and t(17,7), have been described so far (13, 18, 28).”
BackgroundVariant translocations of chromosome 22 in Ewing's sarcoma
Squire, J. A., Zieleńska, M., Thorner, P. S., Tennyson, S., Weitzman, S. S., Pai, K. M., Yeger, H., Ng, Y., & Weksberg, R. (1993) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870080309 · Cited by 31
Molecular Genetics in the Diagnosis and Prognosis of Solid Pediatric Tumors
Thorner, P. S., & Squire, J. A. (1998) · Pediatric and Developmental Pathology · doi:10.1007/s100249900049 · Cited by 33
Pagani, A., Fischer‐Colbrie, R., Eder, U., Pellı́n, A., Llombart‐Bosch, A., & Bussolati, G. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630522 · Cited by 31
Dehner, C. A., Warmke, L. M., Umphress, B. A., Malik, F. A., Cloutier, J. M., Dermawan, J. K. T. K., Fritz, M., Que, S. K. T., Ameline, B., Fritchie, K., et al. (2024) · Modern Pathology · doi:10.1016/j.modpat.2024.100656 · Cited by 30
The dynamic and heterogeneous composition of biomolecular condensates and its functional relevance
Sang, C. C., Upadhyay, S., Nosella, M. L., Forman-Kay, J. D., & Lee, H. O. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00897-2 · Cited by 48
Chromosomal Aberrations in Solid Tumors
Chinnaiyan, A. M., & Palanisamy, N. (2010) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385071-3.00004-6 · Cited by 33
Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage response
Gorthi, A., & Bishop, A. J. R. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1465014 · Cited by 30
“In over 85% of patients, the translocation is between chromosomes 22 and 11, fusing the N-terminal transactivation domain of the EWS RNA binding protein 1 (EWSR1) gene to the C-terminal DNA binding domain of the weak transcription factor Fli-1 proto-oncogene, ETS transcription factor (FLI1) gene.(1) The resultant EWS-…”
BackgroundSong, J., Yuan, C., Yang, J., Liu, T., Yao, Y., Xiao, X., Gajendran, B., Xu, D., Li, Y., Wang, C., et al. (2018) · FEBS Journal · doi:10.1111/febs.14690 · Cited by 31
Cao, M., Zhang, M., Yang, N., Fu, Q., Su, B., Zhang, X., Li, Q., Yan, X., Thongda, W., & Li, C. (2020) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2020.09.015 · Cited by 32
Hosoya, Y., & Ohkanda, J. (2021) · Molecules · doi:10.3390/molecules26082118 · Cited by 32
“Ewing’s Sarcoma-Friend Leukemia Integration 1 (EWS-FLI1) Ewing’s sarcoma (EWS) is a bone and soft tissue carcinoma that produces an Ewing’s sarcoma–Friend leukemia integration 1 (EWS-FLI1) fusion protein, which is a transcription factor that may be a drug target for the disease [82,83].”
BackgroundAdvances in the Treatment of Pediatric Bone Sarcomas
Grohar, P. J., Janeway, K. A., Maese, L. D., & Schiffman, J. D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175378 · Cited by 33
“This has led to the identification of a number of compounds that fit the following criteria of being EWSR1-FLI1 inhibitors to varying degrees: (1) impact expression of specific downstream targets of EWSR1-FLI1 such as NR0B1; (2) reverse established EWSR1-FLI1 genome-wide signatures using approaches such as gene set en…”
MethodERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
Magistroni, V., Mologni, L., Sanselicio, S., Reid, J. F., Redaelli, S., Piazza, R., Viltadi, M., Bovo, G., Strada, G., Grasso, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028162 · Cited by 30
“ERG and FUS/ERG fusion proteins have been described in a subset of Ewing sarcoma [3,4] and in acute myeloid leukaemia [5– 7].”
BackgroundNew Strategies in Ewing Sarcoma: Lost in Translation?
Arnaldez, F. I., & Helman, L. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0633 · Cited by 31
Granowetter, L., & West, D. C. (1997) · Cancer treatment and research · doi:10.1007/978-1-4615-5767-8_9 · Cited by 34
Prognostic factors in soft tissue sarcoma
Levine, E. A. (1999) · Seminars in Surgical Oncology · doi:10.1002/(sici)1098-2388(199907/08)17:1<23::aid-ssu4>3.0.co;2-r · Cited by 98
hTERT Is Highly Expressed in Ewing???s Sarcoma and Activated by EWS-ETS Oncoproteins
Fuchs, B., Inwards, C. Y., Scully, S. P., & Janknecht, R. (2004) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000141385.77071.8d · Cited by 30
“More than a decade ago, the first translocation specific for Ewing’s sarcoma was identified.(5) Such a genetic rearrangement generates a EWS-ETS fusion protein in which the N-terminal domain is derived from the Ewing’s sarcoma EWS gene product and the C-terminal domain of a DNA-binding domain is derived from one of fi…”
BackgroundPalombo, R., Frisone, P., Fidaleo, M., Mercatelli, N., Sette, C., & Paronetto, M. P. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2403 · Cited by 29
Fusion transcripts: Unexploited vulnerabilities in cancer?
Neckles, C., Rajan, S. S., & Caplen, N. J. (2019) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1562 · Cited by 30
“(Delattre et al., 1992; May et al., 1993; Sorensen et al., 1994).”
Therapeutic Potential of EWSR1–FLI1 Inactivation by CRISPR/Cas9 in Ewing Sarcoma
Cervera, S. T., Rodriguez‐Martin, C., Fernández-Tabanera, E., de Mera, R. M. M.-F., Morin, M., Fernández-Peñalver, S., Iranzo-Martínez, M., Amhih-Cardenas, J., García‐García, L., González‐González, L., et al. (2021) · Cancers · doi:10.3390/cancers13153783 · Cited by 32
“The most frequent of these fusions proteins is EWSR1–FLI1 in which the N-terminal region of the EWSR1 gene is fused to the C-terminal region of the transcription factor FLI1 containing the DNA binding domain [6].”
BackgroundRepair Foci as Liquid Phase Separation: Evidence and Limitations
Miné-Hattab, J., Liu, S., & Taddei, A. (2022) · Genes · doi:10.3390/genes13101846 · Cited by 33
“EWS fusion is at the origin of pediatric tumors [15]; its depletion reduces cell viability upon UV-irradiations [16] and Ewing sarcoma cells are sensitive to PARP inhibitors [17].”
BackgroundPeripheral primitive neuroectodermal tumor of the stomach in a 14-year-old boy: a case report
Czekalla, R., Fuchs, M., lzle, A. S., Nerlich, M. L., Poremba, C., Schaefer, K., Weirich, G., H??fler, H., Schneller, F., Peschel, C., et al. (2004) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200412000-00026 · Cited by 30
Coutte, L., Monté, D., Imai, K., Pouilly, L., Dewitte, F., Vidaud, M., Adamski, J., Baert, J., & de Launoit, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1203020 · Cited by 29
“Some of these genes become oncogenic by retroviral insertional mutagenesis (Moreau-Gachelin et al., 1988; Ben David et al., 1991) or by chromosomal translocations in myeloid leukemia (Shimizu et al., 1993; Golub et al., 1994) and Ewing's sarcomas (Delattre et al., 1992; Zucman et al., 1993).”
BackgroundFears, S. C., Vignon, C., Bohlander, S. K., Smith, S. D., Rowley, J. D., & Nucifora, G. (1996) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199610)17:2<127::aid-gcc8>3.0.co;2-7 · Cited by 59
Szuhai, K., IJszenga, M. J., Tanke, H. J., Taminiau, A. H. M., de Schepper, A., van Duinen, S. G., Rosenberg, C., & Hogendoorn, P. C. W. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.07.007 · Cited by 31
Melot, T., Gruel, N., Doubeikovski, A., Sévenet, N., Teillaud, J., & Delattre, O. (1997) · Hybridoma · doi:10.1089/hyb.1997.16.457 · Cited by 30
Self-citationvan Roggen, J. F. G., Bovée, J. V. M. G., Morreau, J., & Hogendoorn, P. C. W. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.7.481 · Cited by 29
Tanaka, M., Yamaguchi, S., Yamazaki, Y., Kinoshita, H., Kuwahara, K., Nakao, K., Jay, P. Y., Noda, T., & Nakamura, T. (2015) · Scientific Reports · doi:10.1038/srep07826 · Cited by 28
Ewing sarcoma protein promotes dissociation of poly(ADP‐ribose) polymerase 1 from chromatin
Lee, S., Kim, N., Kim, S., Park, I. B., Kim, H.-J., Kim, S., Kim, B., Hwang, J. M., Baek, I., Gartner, A., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948676 · Cited by 29
“The EWS gene was originally identified at the breakpoint of the Ewing sarcoma chromosomal translocation t(11;22)(q24;q12), which results in a fusion protein of the EWS and the Friend leukemia virus integration site 1 (FLI1) protein (Delattre et al , 1992).”
Vermeulen, J., Ballet, S., Oberlin, O., Peter, M., Pierron, G., Longavenne, E., Laurence, V., Kanold, J., Chastagner, P. B., Lejars, O., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603438 · Cited by 28
“…factor genes FLI, ERG, or FEV in approximately 87%, 10%, and less than 1% of tumours, or ETV1 or E1AF in rare cases, respectively (Turc-Carel et al, 1983; Delattre et al, 1992; Zucman et al, 1993; Sorensen et al, 1994; Jeon et al, 1995; Kaneko et al, 1996; Peter et al, 1997; Kovar, 1998).”
BackgroundSelf-citationKawagoe, H., Potter, M. D., Ellis, J., & Grosveld, G. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0839 · Cited by 32
“In particular, chromosomal translocations involving these genes provide direct evidence that the ETS family of genes is linked to human hematopoiesis/oncogenesis (9, 10).”
BackgroundCytogenomics of cancers: From chromosome to sequence
Bernheim, A. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.06.003 · Cited by 28
“…new hybrid gene is malignancy-specific as for example the FLI1-EWS fusion gene following the t(11; 22) (q24, q12) translocation in Ewing’s sarcoma (Delattre et al., 1992, 1994; Riggi and Stamenkovic, 2007) or the EML4-ALK fusion gene following an inversion on 2p in lung carcinoma (Soda et al.,…”
BackgroundSong, W., Li, W., Li, L., Zhang, S., Xu, Y., Wen, X., Zhang, X., Tian, H., Li, A., Hu, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4350 · Cited by 29
“The EWS/FLI1 oncoprotein is formed by t(11;22) (q24;q12) rearrangement, in which FLI1 becomes juxtaposed 3’ to the EWS gene [18].”
Shelake, S., Sankpal, U. T., Bowman, W. P., Wise, M., Ray, A., & Basha, R. M. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0417-9 · Cited by 28
“The characteristic feature of ES is the presence of EWS-FLI1, a chimeric protein formed by the translocation between EWS and FLI1, in approximately 85% of cases [5], while 10–15% of ES cases harbor variants of translocation between EWS and ERG genes [6].”
BackgroundMora, J., Castañeda, A., Pérez‐Jaume, S., Pousa, A. L., Maradiegue, E., Valverde, C. M., Martín‐Broto, J., del Muro, X. G., Cruz, O., Cruz, J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.252 · Cited by 28
“It is characterised by reciprocal translocations that result in the fusion of the EWS RNA binding protein 1 (EWSR1) to an ETS transcription factor, EWSR1–FLI1 being the most common chimera (Delattre et al, 1992; Sorensen et al, 1994).”
BackgroundDucimetière, F., Lurkin, A., Ranchère‐Vince, D., Decouvelaere, A.-V., Isaac, S., Claret-Tournier, C., Suignard, Y., Salameire, D., Cellier, D., Alberti, L., et al. (2010) · PubMed · doi:10.1684/bdc.2010.1117 · Cited by 38
An Unusual Location of Extraosseous Ewing's Sarcoma
Geens, L., Robays, J. V., Verswijvel, G., & der Speeten, K. V. (2013) · Case Reports in Oncology · doi:10.1159/000351836 · Cited by 28
Detection of SYT-SSX Fusion Gene in Peripheral Blood From a Patient With Synovial Sarcoma
Hashimoto, N., Myoui, A., Araki, N., Asai, T., Sonobe, H., Hirota, S., & Yoshikawa, H. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200103000-00017 · Cited by 28
Zhang, D., & Childs, G. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.6868 · Cited by 28
Feng, L., & Lee, K. A. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204522 · Cited by 30
“Another similarity is the presence of a repetitive primary structure (Delattre et al., 1992) which, for the EAD, consists of thirty-one copies of Oncogene (2001) 20, 4161 ± 4168 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc *Correspondence: KAW Lee;…”
BackgroundInfluentialTakeuchi, T., Iwasaki, H., Ohjimi, Y., Ohshima, K., Kaneko, Y., Ishiguro, M., Hiratsuka, Y., Sakamoto, K., & Kikuchi, M. (1997) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199712000-00002 · Cited by 28
Ewing sarcoma: The pediatrician's point of view
Marec‐Bérard, P., & Philip, T. O. (2003) · Pediatric Blood & Cancer · doi:10.1002/pbc.10473 · Cited by 28
“Over 95% of cases are characterized by a re-arrangement of chromosome 22, generally t(11;22)(q24;q12) translocation, resulting in EWS– Fli1 fusion [3,4].”
Saulnier, O., Guedri, K., Aynaud, M.-M., Chakraborty, A., Bruyr, J., Pineau, J., O’Grady, T. M., Mirabeau, O., Grossetête, S., Galvan, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab305 · Cited by 30
“These include prostate cancers (4), myeloid leukemias (5) and Ewing sarcoma (6), a highly aggressive bone and soft tissue tumor.”
BackgroundSelf-citationLiebsch, L., Kailayangiri, S., Beck, L., Altvater, B., Koch, R., Dierkes, C., Hotfilder, M., Nagelmann, N., Faber, C., Kooijman, H., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.356 · Cited by 27
“Ewing sarcoma is a cancer of bone and soft tissue that is characterised by a molecular rearrangement of the EWS gene on chromosome 22 with an ets-type gene (Delattre et al, 1992).”
BackgroundUchiumi, F., Miyazaki, S., & Tanuma, S.-I. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0674-x · Cited by 31
Lynn, M. A., Wang, Y., Slater, J., Shah, N., Conroy, J., Ennis, S., Morris, T., Betts, D. R., Fletcher, J. A., & O’Sullivan, M. J. (2013) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31827a47f9 · Cited by 27
Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma
Werner, S., Mendoza, A., Hilger, R. A., Erlacher, M., Reichardt, W., Lissat, A., Konanz, C., Uhl, M., Niemeyer, C. M., Khanna, C., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0566-9 · Cited by 27
“The tumors are of neuroectodermal origin and are characterized by a translocation between the EWS gene and a member of the ETS family of transcription factors [2].”
BackgroundRecent advances in animal models of systemic sclerosis
Asano, Y. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13185 · Cited by 27
Parafioriti, A., Bason, C., Armiraglio, E., Calciano, L., Daolio, P. A., Berardocco, M., Bernardo, A. D., Colosimo, A., Luksch, R., & Berardi, A. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050656 · Cited by 27
EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells
Mutz, C., Schwentner, R., Aryee, D. N. T., Bouchard, E. D. J., Mejia, E. M., Hatch, G. M., Kauer, M. O., Katschnig, A. M., Ban, J., Garten, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14976 · Cited by 28
“This aberrant transcription factor results from the translocation t(11;22)(q24;q12) fusing the Ewing sarcoma breakpoint region 1 (EWSR1) gene with Friend leukemia virus integration site 1 (FLI1) in 85% of EwS [17, 18].”
BackgroundSelf-citationBaldwin, P., Likhotvorik, R. I., Baig, N., Cropper, J. D., Carlson, R., Kurmasheva, R. T., & Sridhar, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01416 · Cited by 27
Inhibition of constitutive NF‐κB activity suppresses tumorigenicity of ewing sarcoma EW7 cells
Javelaud, D., Poupon, M., Wietzerbin, J., & Besançon, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.10192 · Cited by 28
France, K. A., Anderson, J. L., Park, A., & Denny, C. T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225433 · Cited by 28
Cervi, D. N., Shaked, Y., Haeri, M., Usenko, T. S., Lee, C. R., Haigh, J. J., Nagy, A., Kerbel, R. S., Yefenof, E., & Ben‐David, Y. (2006) · Blood · doi:10.1182/blood-2005-11-026823 · Cited by 27
Ewing’s sarcoma of the cervix, a diagnostic dilemma: a case report and review of the literature
Mashriqi, N., Gujjarlapudi, J. K., Sidhu, J. S., Zur, M., & Yalamanchili, M. (2015) · Journal of Medical Case Reports · doi:10.1186/s13256-015-0733-2 · Cited by 27
“3, is seen in 85–90 % of cases [10, 11].”
Cmogenetic Analysis In The Examination Of Solid Tumors In Children
Mertens, F., Mandahl, N., Mitelman, F., & Heim, S. (1994) · Pediatric Hematology and Oncology · doi:10.3109/08880019409140536 · Cited by 27
Molecular Genetic Analysis of a Small Bowel Primitive Neuroectodermal Tumor
Graham, D. K., Stork, L. C., Wei, Q., Ingram, J. D., Karrer, F. M., Mierau, G. W., & Lovell, M. A. (2002) · Pediatric and Developmental Pathology · doi:10.1007/s10024-001-0192-1 · Cited by 27
Delva, L., Gallais, I., Guillouf, C., Denis, N., Orvain, C., & Moreau-Gachelin, F. (2004) · Oncogene · doi:10.1038/sj.onc.1207578 · Cited by 26
“pCS3-MT, pCS3-MT-E1A, pCS3-MT-Spi-1, pCS3-MT-TLS, pCS3-MT-AD-RGG1, pCS3-MT-RRM, pCS3-MT-RGG2-3, pGEX-Spi-1, pGEX-TLS and pGEX-Fli-1 were previously described (Hallier et al., 1998; Lerga et al., 2001). pCS3-MTN163, pCS3-MT-DBD, pCS3-MT-D101 and pCS3-MT-DCter were generated by PCR amplification of the appropriate regio…”
BackgroundInfluentialQadir, M. A., Zhan, S. H., Kwok, B., Bruestle, J., Drees, B., Popescu, O., & Sorensen, P. H. B. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.01.002 · Cited by 26
Ewing sarcoma EWS protein regulates midzone formation by recruiting Aurora B kinase to the midzone
Park, H., Turkalo, T. K., Nelson, K., Folmsbee, S. S., Robb, C. M., Roper, B., & Azuma, M. (2014) · Cell Cycle · doi:10.4161/cc.29337 · Cited by 28
“%) of Ewing sarcoma patients have a common molecular abnormality, the t(11; 22) chromosomal translocation, which results in the expression of a chimeric fusion protein containing EWS (also known as EWSR1)-derived sequences at the N-terminus fused to the carboxyl-terminus of the ETS transcription factor FLI1.”
BackgroundTheisen, E. R., Miller, K. R., Showpnil, I. A., Taslim, C., Pishas, K. I., & Lessnick, S. L. (2019) · Genes & Cancer · doi:10.18632/genesandcancer.188 · Cited by 27
“The resulting pathognomonic fusion protein EWS/FLI functions as an oncogenic transcription factor [1, 5, 6].”
BackgroundExosomes secreted under hypoxia enhance stemness in Ewing’s sarcoma through miR-210 delivery
Kling, M. J., Chaturvedi, N. K., Kesherwani, V., Coulter, D. W., McGuire, T. R., Sharp, J. G., & Joshi, S. S. (2020) · Oncotarget · doi:10.18632/oncotarget.27702 · Cited by 29
“In 85% of patients, EWS is driven by a chromosomal translocation, t [11, 22] (q24; q12), that results in the fusion protein, EWS-FLI1, which has been shown to regulate key pathways involved in EWS tumorigenesis [2, 3].”
BackgroundBuchou, C., Laud-Duval, K., van der Ent, W., Grossetête, S., Zaïdi, S., Gentric, G., Corbé, M., Müller, K., Nery, E. D., Surdez, D., et al. (2022) · Cancers · doi:10.3390/cancers14092327 · Cited by 27
“EwS is caused by a chromosomal translocation that fuses the N-terminal prion-like domain of the EWSR1 protein with the C-terminal DNA-binding domain of an ETS transcription factor, most frequently FLI1 [2,3].”
BackgroundSelf-citationGuinot, A., Tabone‐Eglinger, S., Isnardi, V., Bahri, H., Surdez, D., Delattre, O., Pierron, G., Villemeur, M., Lapouble, E., Brahmi, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.002 · Cited by 26
Self-citationEpigenetic Control of Translation Checkpoint and Tumor Progression via RUVBL1‐EEF1A1 Axis
Li, M., Yang, L., Chan, A., Pokharel, S. P., Liu, Q., Mattson, N., Xu, X., Chang, W., Miyashita, K., Singh, P. A., et al. (2023) · Advanced Science · doi:10.1002/advs.202206584 · Cited by 30
Targeted Therapy for EWS-FLI1 in Ewing Sarcoma
Gong, H., Xue, B., Ru, J., Pei, G., & Li, Y. (2023) · Cancers · doi:10.3390/cancers15164035 · Cited by 27
“EwS is genetically distinct because of a balanced chromosomal translocation that joins the N-terminus of EWS (on chromosome 22) with a gene from the C-terminus of the E-twenty-six (ETS) family of transcription factors (FLI1, ERG, ETV1, ETV5, and FEV), predominantly FLI1 (85%, on chromosome 11) and ERG (10%, on chromos…”
Backgroundγ-Glutamyl transpeptidase expression in Ewing's sarcoma cells:up-regulation by interferons
Bouman, L., Sancéau, J., Rouillard, D., & Bauvois, B. (2002) · Biochemical Journal · doi:10.1042/bj20011854 · Cited by 34
Asano, Y., & Trojanowska, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074930 · Cited by 27
“involved in the development of Ewing sarcoma and related subtypes of primitive neuroectodermal tumors [3], suggesting that Fli1 plays an important role in the process of cellular transforma-”
BackgroundEWS ‐ FLI 1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma
Shimizu, R., Tanaka, M., Tsutsumi, S., Aburatani, H., Yamazaki, Y., Homme, M., Kitagawa, Y., & Nakamura, T. (2018) · Cancer Science · doi:10.1111/cas.13710 · Cited by 27
Renal primitive neuroectodermal tumor: An immunohistochemical and cytogenetic analysis
Takeuchi, T., Iwasaki, H., Ohjimi, Y., Kaneko, Y., Ishiguro, M., Fujita, C., Mlura, Y., Hiratsuka, Y., Sakamoto, K., & Kikuchi, M. (1996) · Pathology International · doi:10.1111/j.1440-1827.1996.tb03613.x · Cited by 26
Ohkura, N., Nagamura, Y., & Tsukada, T. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21876 · Cited by 26
“EWS possesses a conserved RNA-recognition motif [Delattre et al., 1992] and can bind to RNA in vitro [Ohno et al., 1994], suggesting that it may be involved in RNA metabolism.”
BackgroundInfluentialOwosho, A. A., Estilo, C. L., Huryn, J. M., Zhang, L., Fletcher, C. D. �., & Antonescu, C. R. (2017) · Head and Neck Pathology · doi:10.1007/s12105-017-0808-z · Cited by 26
High Specificity of BCL11B and GLG1 for EWSR1-FLI1 and EWSR1-ERG Positive Ewing Sarcoma
Orth, M. F., Hölting, T. L. B., Dallmayer, M., Wehweck, F. S., Paul, T., Musa, J., Baldauf, M. C., Surdez, D., Delattre, O., Knott, M. M. L., et al. (2020) · Cancers · doi:10.3390/cancers12030644 · Cited by 26
Self-citationKleinbaum, L. A., Duggan, C. R., Ferreira, E., Coffey, G., Butticè, G., & Burton, F. H. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1493 · Cited by 29
Schaefer, K., Wai, D., Poremba, C., Korsching, E., van Valen, F., Ozaki, T., Boecker, W., & Dockhorn‐Dworniczak, B. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-001-0558-9 · Cited by 26
“In 85% of ETs, the characteristic t(11;22)(q24;q12) rearrangement generates a EWS-FLI1 fusion transcript encoded by the derivative 22 [ 7 , 9]. In the remaining 15% of the cases, variant chromosome-22 translocations result in in-frame gene fusions with ERG [12, 32, 41], ETV1 [17], E1AF [18], and FEV [27].”
BackgroundPopulation-based genetic alterations in Ewing’s tumors from Japanese and European Caucasian patients
Ozaki, T., Schaefer, K., Wai, D., Yokoyama, R., Ahrens, S., Diallo, R. I., Hasegawa, T., Shimoda, T., Hirohashi, S., Kawai, A., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf218 · Cited by 29
“Ewing’s tumors are mainly composed of small round tumor cells characterized by specific chromosomal translocations; the most frequent translocation partner of EWS (22q12) is FLI1 (11q24) which occurs in 90–95% of cases [2–4], followed by ERG (21q22) in 5–10% of cases [5, 6].”
BackgroundFluorescence in Situ Hybridization: Molecular Probes for Diagnosis of Pediatric Neoplastic Diseases
Raimondi, S. C. (2000) · Cancer Investigation · doi:10.3109/07357900009038245 · Cited by 27
Enguita‐Germán, M., Schiapparelli, P. V., REY, J. A., & Castresana, J. S. (2010) · Tumor Biology · doi:10.1007/s13277-010-0046-4 · Cited by 26
“This protein increases proliferation [ 37 ] and reduces apoptosis [38, 39].”
Background
Metadata
- Authors
- Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., Aurias, A., & Thomas, G.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Nature
- Published
- 1992-09
- Volume
- 359
- Issue
- 6391
- Pages
- 162-165
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2069351898
- Cited by
- 1,907
- References
- 30
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 69 · 2023: 64 · 2022: 78 · 2021: 83 · 2020: 80 · 2019: 69 · 2018: 54 · 2017: 57 · 2016: 71 · 2015: 62 · 2014: 61 · 2013: 63 · 2012: 45
- FWCI
- 60.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- Ewing sarcoma, primitive neuroectodermal tumor, 22)(q24, EWSR1, gene fusion, chromosomal translocation, RNA-binding domain
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 22, Cloning, Molecular, Gene Frequency, Humans, Molecular Sequence Data, Nucleic Acid Hybridization, Sarcoma, Ewing, Sequence Homology, Nucleic Acid, Transcription, Genetic, Translocation, Genetic, Restriction Mapping, DNA Probes, Polymerase Chain Reaction, Open Reading Frames, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.